These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 22314198)
21. Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study. Panuccio V; Cutrupi S; Pizzini P; Mallamaci F; Tripepi G; Zoccali C Am J Kidney Dis; 2007 Dec; 50(6):1001-8. PubMed ID: 18037100 [TBL] [Abstract][Full Text] [Related]
22. Analytical and clinical evaluation of a method to quantify bone alkaline phosphatase, a marker of osteoblastic activity. Martin M; Van Hoof V; Couttenye M; Prove A; Blockx P Anticancer Res; 1997; 17(4B):3167-70. PubMed ID: 9329628 [TBL] [Abstract][Full Text] [Related]
23. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. Grzegorzewska AE; Młot M Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342 [TBL] [Abstract][Full Text] [Related]
24. Correlation of serum magnesium with serum parathormone levels in patients on regular hemodialysis. Baradaran A; Nasri H Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):344-50. PubMed ID: 16970254 [TBL] [Abstract][Full Text] [Related]
25. Leptin and biochemical markers of bone turnover in dialysis patients. Zoccali C; Panuccio V; Tripepi G; Cutrupi S; Pizzini P; Mallamaci F J Nephrol; 2004; 17(2):253-60. PubMed ID: 15293526 [TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of PTH (1-84) and PTH (7-84) in patients with predialysis chronic renal failure in relation to bone metabolism markers]. Tsuchida T; Ishimura E; Hirowatari K; Matsumoto N; Jono S; Miki T; Inaba M; Nishizawa Y Clin Calcium; 2005 Sep; 15 Suppl 1():156-60; discussion 160. PubMed ID: 16272650 [TBL] [Abstract][Full Text] [Related]
27. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383 [TBL] [Abstract][Full Text] [Related]
28. Parathyroid hormone gene polymorphism and secondary hyperparathyroidism in hemodialysis patients. Gohda T; Shou I; Fukui M; Funabiki K; Horikoshi S; Shirato I; Tomino Y Am J Kidney Dis; 2002 Jun; 39(6):1255-60. PubMed ID: 12046039 [TBL] [Abstract][Full Text] [Related]
29. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Lertdumrongluk P; Lau WL; Park J; Rhee CM; Kovesdy CP; Kalantar-Zadeh K Nephrol Dial Transplant; 2013 Oct; 28(10):2535-45. PubMed ID: 23904397 [TBL] [Abstract][Full Text] [Related]
30. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Sardiwal S; Gardham C; Coleman AE; Stevens PE; Delaney MP; Lamb EJ Kidney Int; 2012 Jul; 82(1):100-5. PubMed ID: 22456600 [TBL] [Abstract][Full Text] [Related]
31. Elevated Alkaline Phosphatase in Infants With Parenteral Nutrition-Associated Liver Disease Reflects Bone Rather Than Liver Disease. Nandivada P; Potemkin AK; Carlson SJ; Chang MI; Cowan E; O'Loughlin AA; Gura KM; Puder M JPEN J Parenter Enteral Nutr; 2015 Nov; 39(8):973-6. PubMed ID: 25106918 [TBL] [Abstract][Full Text] [Related]
33. The Novel Bone Alkaline Phosphatase Isoform B1x Is Associated with Improved 5-Year Survival in Chronic Kidney Disease. Haarhaus M; Fernström A; Qureshi AR; Magnusson P Nutrients; 2021 Dec; 13(12):. PubMed ID: 34959954 [TBL] [Abstract][Full Text] [Related]
34. Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases. Gonnelli S; Cepollaro C; Montagnani A; Monaci G; Campagna MS; Franci MB; Gennari C Eur J Clin Invest; 1996 May; 26(5):391-6. PubMed ID: 8796366 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of serum bone alkaline phosphatase activity in patients with liver disease: Comparison between electrophoresis and chemiluminescent enzyme immunoassay. Zhan F; Watanabe Y; Shimoda A; Hamada E; Kobayashi Y; Maekawa M Clin Chim Acta; 2016 Sep; 460():40-5. PubMed ID: 27291655 [TBL] [Abstract][Full Text] [Related]
36. Mass versus activity: validation of an immunometric assay for bone alkaline phosphatase in serum. Price CP; Mitchell CA; Moriarty J; Gray M; Noonan K Ann Clin Biochem; 1995 Jul; 32 ( Pt 4)():405-12. PubMed ID: 7486801 [TBL] [Abstract][Full Text] [Related]
37. A case series of benign transient hyperphosphatasemia from a pediatric endocrinology reference health facility in Turkey. Dursun F; Kirmizibekmez H Pan Afr Med J; 2018; 30():206. PubMed ID: 30574225 [TBL] [Abstract][Full Text] [Related]
38. Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum. Van Hoof VO; Martin M; Blockx P; Prove A; Van Oosterom A; Couttenye MM; De Broe ME; Lepoutre LG Clin Chem; 1995 Jun; 41(6 Pt 1):853-7. PubMed ID: 7768003 [TBL] [Abstract][Full Text] [Related]